Faron Pharmaceuticals Oy has announced the appointment of Yrj Wichmann as the Company's permanent Chief Financial Officer (CFO). Mr. Wichmann, who has been serving as the interim CFO since April 2024, brings over 20 years of experience in financing and investment banking. His previous roles include serving as the Company's CFO between 2014 and 2019 and as Senior Vice President, Financing & IR from 2019 to April 2024. Faron's CEO, Dr. Juho Jalkanen, expressed his pleasure at Mr. Wichmann's appointment, highlighting his pivotal role in the financial turnaround of the company. Mr. Wichmann also expressed his enthusiasm for the new role and the exciting phase Faron is entering.
The company is currently focused on advancing bexmarilimab, its investigational immunotherapy, through clinical development. Bexmarilimab is being investigated in an open-label Phase 1/2 clinical trial for the treatment of aggressive hematological malignancies, specifically acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The primary objective of the trial is to determine the safety and tolerability of bexmarilimab in combination with standard of care (SoC) treatment. The therapy is designed to target Clever-1, an immunosuppressive receptor found on macrophages, with the aim of reprogramming myeloid cell function and igniting the immune system to overcome resistance to existing treatments and optimize clinical outcomes.
Faron Pharmaceuticals Ltd. is a global, clinical-stage biopharmaceutical company focused on developing novel immunotherapies to tackle cancers. Its lead asset, bexmarilimab, is a humanized antibody with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. The company's mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. For more information, visit www.faron.com.
The announcement also includes contact information for investor and media inquiries, as well as details about the ongoing BEXMAB study and the company's focus on forward-looking statements.